MSD snags European approval for pulmonary arterial hypertension therapy
Winrevair is the first approved activin signaling pathway-targeting therapy for the treatment of the rare blood vessel disorder.
Winrevair is the first approved activin signaling pathway-targeting therapy for the treatment of the rare blood vessel disorder.
What's Your Reaction?
